Arcus Biosciences, Inc.
RCUS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $258,000 | $117,000 | $112,000 | $383,000 |
| % Growth | 120.5% | 4.5% | -70.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $258,000 | $117,000 | $112,000 | $383,000 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $448,000 | $340,000 | $288,000 | $257,000 |
| G&A Expenses | $120,000 | $117,000 | $104,000 | $72,000 |
| SG&A Expenses | $120,000 | $117,000 | $104,000 | $72,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $20,000 | $0 | $0 | $0 |
| Operating Expenses | $588,000 | $457,000 | $392,000 | $329,000 |
| Operating Income | -$330,000 | -$340,000 | -$280,000 | $54,000 |
| % Margin | -127.9% | -290.6% | -250% | 14.1% |
| Other Income/Exp. Net | $47,000 | $39,000 | $14,000 | $1,000 |
| Pre-Tax Income | -$283,000 | -$301,000 | -$266,000 | $55,000 |
| Tax Expense | $1,000 | $6,000 | $1,000 | $2,000 |
| Net Income | -$283,000 | -$307,000 | -$267,000 | $53,000 |
| % Margin | -109.7% | -262.4% | -238.4% | 13.8% |
| EPS | -3.14 | -4.15 | -3.71 | 0.76 |
| % Growth | 24.3% | -11.9% | -588.2% | – |
| EPS Diluted | -3.14 | -4.15 | -3.71 | 0.71 |
| Weighted Avg Shares Out | 90,100 | 74,000 | 72,000 | 69,345 |
| Weighted Avg Shares Out Dil | 90,100 | 74,000 | 72,000 | 73,966 |
| Supplemental Information | – | – | – | – |
| Interest Income | $52,000 | $41,000 | $16,000 | $1,000 |
| Interest Expense | $4,000 | $2,000 | $2,000 | $0 |
| Depreciation & Amortization | $10,000 | $8,000 | $6,000 | $4,000 |
| EBITDA | -$269,000 | -$291,000 | -$258,000 | $59,000 |
| % Margin | -104.3% | -248.7% | -230.4% | 15.4% |